지중해빈혈 진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 최종사용자별, 지역별, 경쟁(2020-2030년)
Thalassemia Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Complete Blood Cell Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others), By End User, By Region and Competition, 2020-2030F
상품코드:1771112
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 지중해빈혈 진단 시장은 2024년에 6억 5,411만 달러로 평가되며, 2030년에는 8억 9,726만 달러에 달하며, CAGR 5.41%로 성장할 것으로 예측됩니다.
이 시장은 전 세계 지중해빈혈 유병률 증가와 이 질병에 대한 사회적 인식이 높아짐에 따라 꾸준히 성장하고 있습니다. 큐어스에 따르면 전 세계 인구의 약 1.5%(약 1억 명)가 B형 지중해빈혈 유전자를 보유하고 있으며, 동남아시아, 중동, 지중해 연안 지역에서 가장 높은 유병률을 보이고 있습니다. 진단에는 전혈구 계산, 헤모글로빈 전기영동, DNA 분석 등 다양한 검사법이 있으며, PCR 및 유전자 검사와 같이 정확성과 민감도가 높은 첨단 진단 기술의 채택이 증가함에 따라 시장 성장을 더욱 촉진하고 있습니다. 정부의 검진 프로그램 강화와 진단 서비스에 대한 광범위한 접근성은 장기적인 질병 관리를 지원하는 발견 및 모니터링 증가에 기여하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
6억 5,411만 달러
시장 규모 : 2030년
8억 9,726만 달러
CAGR : 2025-2030년
5.41%
급성장 부문
DNA 검사
최대 시장
북미
시장 성장 촉진요인
유행 지역에서의 지중해빈혈 유병률 상승
주요 시장 이슈
저소득 지역의 진단 서비스 접근성 제한
주요 시장 동향
유전 상담 및 진단 서비스 통합
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 COVID-19가 세계의 지중해빈혈 진단 시장에 미치는 영향
제6장 임상시험 분석
제7장 세계의 지중해빈혈 진단 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
유형별(전혈구(CBC) 검사, 헤모글로빈 검사, 철결핍 검사, DNA 검사, 기타)
최종사용자별(병원·진료소, 진단 연구소, 기타)
지역별
기업별(2024년)
시장 맵
유형별
최종사용자별
지역별
제8장 북미의 지중해빈혈 진단 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제9장 유럽의 지중해빈혈 진단 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
스페인
이탈리아
제10장 아시아태평양의 지중해빈혈 진단 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
말레이시아
태국
베트남
제11장 남미의 지중해빈혈 진단 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제12장 중동 및 아프리카의 지중해빈혈 진단 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제13장 시장 역학
촉진요인
과제
제14장 시장 동향과 발전
제품 출시
합병과 인수
최근 동향
제15장 세계의 지중해빈혈 진단 시장 : SWOT 분석
제16장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제17장 경쟁 구도
Hybribio Limited
Oasis Diagnostics Corporation
ViennaLab Diagnostics GmbH
GENETEK BIOPHARMA GmbH
Devyser Diagnostics AB
YANENG BIOSCIENCE(SHENZHEN) CO.,LTD.
BioLab Diagnostics India Private Limited
NPT Co. Ltd.
Bio-Rad Laboratories, Inc.
Chiesi Farmaceutici S.p.A
제18장 전략적 제안
제19장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Thalassemia Diagnostic Market was valued at USD 654.11 million in 2024 and is projected to reach USD 897.26 million by 2030, growing at a CAGR of 5.41%. This market is expanding steadily due to the increasing global prevalence of thalassemia and heightened public awareness surrounding the disease. According to Cureus, approximately 1.5% of the global population-or about 100 million individuals-carry the B-thalassemia gene, with the highest prevalence found in Southeast Asia, the Middle East, and Mediterranean regions. The diagnostic landscape includes a variety of testing methods such as complete blood count, hemoglobin electrophoresis, and DNA analysis. Rising adoption of advanced diagnostic technologies like PCR and genetic testing, known for their precision and sensitivity, is further propelling market growth. Enhanced governmental screening programs and broader access to diagnostic services are also contributing to increased detection and monitoring, supporting long-term disease management.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 654.11 Million
Market Size 2030
USD 897.26 Million
CAGR 2025-2030
5.41%
Fastest Growing Segment
DNA Tests
Largest Market
North America
Key Market Drivers
Rising Prevalence of Thalassemia in Endemic Regions
The increasing prevalence of thalassemia, particularly in high-burden areas such as Southeast Asia, the Middle East, and parts of the Mediterranean, is a primary driver of the Global Thalassemia Diagnostic Market. Thalassemia is a hereditary blood disorder marked by reduced or absent hemoglobin production, often requiring lifelong treatment. WHO estimates that roughly 5% of the global population carries a gene for hemoglobin disorders, including thalassemia.
In countries like India and Pakistan, an estimated 8,000 to 10,000 children are born each year with thalassemia major-a severe form that requires routine transfusions and early diagnosis for effective care. National governments are increasingly rolling out preventive and screening initiatives. For instance, India's Ministry of Health has incorporated thalassemia screening into the Rashtriya Bal Swasthya Karyakram (RBSK), focusing on early genetic disorder detection. Thailand's national prevention strategy, which includes carrier screening and premarital counseling, has significantly reduced the birth rate of severe cases. These efforts are encouraging wider diagnostic adoption, driving market growth.
Key Market Challenges
Limited Access to Diagnostic Services in Low-Income Regions
Despite advances in testing technologies, many low-income and rural regions still lack adequate access to thalassemia diagnostics. This is especially pronounced in Sub-Saharan Africa, Southeast Asia, and certain parts of South America, where healthcare infrastructure remains underdeveloped. According to WHO, numerous high-burden countries have yet to implement national screening policies or structured care programs.
Diagnostic facilities are often concentrated in urban centers, leaving rural populations underserved. Additionally, in many low-income economies, out-of-pocket costs make diagnostic services financially inaccessible. The World Bank reports that over 40% of healthcare expenses in these regions are directly paid by patients, which discourages early screening unless symptoms are severe. The lack of trained personnel, equipment, and government support further compounds the challenge, making early and accurate diagnosis difficult for vulnerable populations.
Key Market Trends
Integration of Genetic Counseling with Diagnostic Services
A notable trend in the Global Thalassemia Diagnostic Market is the integration of genetic counseling into diagnostic workflows, particularly in regions with high carrier prevalence. Genetic counseling helps individuals understand the inheritance patterns, risks, and management options related to thalassemia, enhancing informed decision-making.
Countries such as Cyprus and Iran have achieved success in reducing thalassemia incidence through mandatory premarital screening programs that include counseling. Iran's national initiative reportedly reduced thalassemia births by over 85% within a decade, demonstrating the effectiveness of pairing diagnostic testing with educational support. This trend highlights a shift toward more comprehensive care models that combine early detection with preventative guidance, contributing to improved outcomes and reduced disease burden.
Key Market Players
Hybribio Limited
Oasis Diagnostics Corporation
ViennaLab Diagnostics GmbH
GENETEK BIOPHARMA GmbH
Devyser Diagnostics AB
YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
BioLab Diagnostics India Private Limited
NPT Co. Ltd.
Bio-Rad Laboratories, Inc.
Chiesi Farmaceutici S.p.A
Report Scope:
In this report, the Global Thalassemia Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Thalassemia Diagnostic Market, By Type:
Complete Blood Cell (CBC) Test
Hemoglobin Test
Iron Deficiency Test
DNA Tests
Others
Thalassemia Diagnostic Market, By End User:
Hospitals & Clinics
Diagnostic Laboratories
Others
Thalassemia Diagnostic Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Thalassemia Diagnostic Market.
Available Customizations:
Global Thalassemia Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Impact of COVID-19 on Global Thalassemia Diagnostics Market
6. Clinical Trial Analysis
6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Breakdown of Pipeline, By Development Phase
6.5. Breakdown of Pipeline, By Status
6.6. Breakdown of Pipeline, By Study Type
6.7. Breakdown of Pipeline, By Region
6.8. Clinical Trials Heat Map
7. Global Thalassemia Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others)
7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
7.2.3. By Region
7.2.4. By Company (2024)
7.3. Market Map
7.3.1. By Type
7.3.2. By End User
7.3.3. By Region
8. North America Thalassemia Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By End User
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Thalassemia Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By End User
8.3.2. Canada Thalassemia Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By End User
8.3.3. Mexico Thalassemia Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By End User
9. Europe Thalassemia Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By End User
9.2.3. By Country
9.3. Europe: Country Analysis
9.3.1. Germany Thalassemia Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By End User
9.3.2. France Thalassemia Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By End User
9.3.3. United Kingdom Thalassemia Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By End User
9.3.4. Spain Thalassemia Diagnostics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By End User
9.3.5. Italy Thalassemia Diagnostics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By End User
10. Asia-Pacific Thalassemia Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By End User
10.2.3. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Thalassemia Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By End User
10.3.2. India Thalassemia Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By End User
10.3.3. Malaysia Thalassemia Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By End User
10.3.4. Thailand Thalassemia Diagnostics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By End User
10.3.5. Vietnam Thalassemia Diagnostics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Type
10.3.5.2.2. By End User
11. South America Thalassemia Diagnostics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By End User
11.2.3. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Thalassemia Diagnostics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By End User
11.3.2. Argentina Thalassemia Diagnostics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By End User
11.3.3. Colombia Thalassemia Diagnostics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By End User
12. Middle East and Africa Thalassemia Diagnostics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Type
12.2.2. By End User
12.2.3. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Thalassemia Diagnostics Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Type
12.3.1.2.2. By End User
12.3.2. Saudi Arabia Thalassemia Diagnostics Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Type
12.3.2.2.2. By End User
12.3.3. UAE Thalassemia Diagnostics Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Type
12.3.3.2.2. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
14.1. Product Launches
14.2. Mergers & Acquisitions
14.3. Recent Developments
15. Global Thalassemia Diagnostics Market: SWOT Analysis
